Reuters: Novo Nordisk oral weight-loss pill faces price war test
Early uptake of the oral semaglutide obesity product runs into competitive pricing pressure in the incretin market.
The wire
- 01Reuters reports strong early demand for Novo Nordisk's oral weight-loss pill alongside mounting pressure on price as rivals compete.
- 02Cash and list pricing for an oral incretin sets the benchmark telehealth operators and pharmacies are measured against.
- 03Actual net prices, payer coverage and how Eli Lilly responds will determine whether the launch momentum holds.
From the source
Read at reuters.comNovo Nordisk's weight-loss pill boom faces price war test